Pharma Penny Stock Under Rs 50 Jumps After Company Successfully Achieved Certificate of Suitability (CEP) for Metformin Hydrochloride from European Directorate
From Rs 34.51 per share (52-week low) to Rs 41.39 per share, the stock is up by 20 per cent. .
Today, shares of Sigachi Industries Ltd gained 2.9 per cent to Rs 41.39 per share from its previous closing of Rs 40.22 per share. The company has a market cap of over Rs 1,300 crore and has delivered good profit growth of 25 per cent CAGR over the last 5 years. From Rs 34.51 per share (52-week low) to Rs 41.39 per share, the stock is up by 20 per cent. .
Sigachi Industries Limited is celebrating a significant achievement as its subsidiary, Trimax Biosciences Pvt Ltd, has been granted the Certificate of Suitability (CEP) for “Metformin Hydrochloride” by the European Directorate for the Quality of Medicines & Health Care (EDQM). This crucial milestone unlocks access for Trimax to export this vital Active Pharmaceutical Ingredient (API) to Europe and other markets that recognise the CEP. This development not only strengthens Sigachi's foothold in highly regulated pharmaceutical landscapes but also underscores the group's dedication to upholding rigorous quality benchmarks and adhering to stringent regulatory requirements.
The CEP certification for Metformin Hydrochloride, a cornerstone in the management of type 2 diabetes with a projected market size of USD 386.91 million by 2030, aligns perfectly with Sigachi’s strategic ambition to expand its presence in strictly regulated regions. This achievement reaffirms Sigachi’s proficiency in meeting the European Union’s demanding standards for safety, efficacy, and Good Manufacturing Practice (GMP). With the widespread global acceptance of Metformin, evidenced by numerous FDA-approved fixed-dose combinations, this certification positions Sigachi to capitalise on the growing demand for this essential pharmaceutical ingredient.
DSIJ’s 'Tiny Treasure' service recommends researched Small-Cap stocks with Inherent Growth Potential. If this interests you, do download the service details here.
About the Company
Sigachi Industries Limited, a publicly traded pharmaceutical company listed on NSE and BSE, is a global leader in providing high-quality excipients, vitamin-mineral nutrient blends, APIs, and O&M services. With over 35 years of industry expertise, Sigachi has built a strong reputation as a trusted partner for pharmaceutical and nutraceutical companies worldwide. They specialise in innovative solutions for food stability, fortification, and nutrition, offering tailored blends of vitamins, minerals, and other ingredients to meet the evolving needs of consumers. By utilising advanced technologies like blending, encapsulation, and spray drying, Sigachi empowers food manufacturers to create products with superior taste, quality, and nutritional value, contributing to a healthier and happier world.
The company announced positive Quarterly Results (Q3FY25) and nine-month results (9MFY24). According to quarterly results, revenue increased by 26 per cent to Rs 139.42 crore, EBITDA increased by 45 per cent to Rs 35.19 crore and consolidated net profit increased by 33 per cent to Rs 21.35 crore in Q3FY25 compared to Q3FY24. In its nine-month results, revenue increased by 22 per cent to Rs 360.03 crore, EBITDA increased by 39 per cent to Rs 89.75 crore and consolidated PAT increased by 33 per cent to Rs 56.29 crore in 9MFY25 compared to 9MFY24.
Disclaimer: The article is for informational purposes only and not investment advice.